520.80 -7.65 (-1.45%)

300.62% Gain from 52W Low

285.1K NSE+BSE Volume

NSEJul 26, 2021 03:31 PM



Hikal Ltd.    
08 May 2021
520.80
-1.45%
buy
ICICI Securities Limited
The Q4 performance was above I-direct estimates across all fronts. Q4 margin performance was the highest in the past five years, showcasing Hikal's focus on high margin products and backward integration besides cost control measures. Going ahead, the management expects a margin improvement of 50-100 bps from this year onwards on the back of several cost rationalisation and efficiency improvement measures undertaken during the pandemic. Going by the capex guidance, (| 200 crore over the next 18 months) things are looking promising for FY22 onwards. Despite the...
Hikal Ltd. has an average target of 345.00 from 2 brokers.
Hikal Ltd.    
08 May 2021
520.80
-1.45%
BP Wealth
Hikal posted revenue of INR 5,325mn with 40.5% YoY growth which was above our estimate of INR 4,859mn mainly driven by strong growth in the both Pharmaceutical and Crop protection segment. On segmental performance: The crop protection segment grew by 54% (YoY) to INR 2348mn on the back of strong volume growth in existing products and commercialization of a new product from their newly built facility in Panoli Pharmaceutical segment revenue surged by 32% to INR 2,977mn based on increased volumes of existing API Generics and CDMO products. During the quarter, the company has filled US DMF for Favipiravir API to supporting both domestic and global markets. Despite 129bps contraction in gross margin, EBITDA margin managed to improve by 188bps to 20.5%, was 142bps...
Number of MF schemes decreased from 11 to 2 in Jun 2021 qtr
Hikal Ltd.    
08 May 2021
520.80
-1.45%
BP Wealth
Hikal posted revenue of INR 5,325mn with 40.5% YoY growth which was above our estimate of INR 4,859mn mainly driven by strong growth in the both Pharmaceutical and Crop protection segment. On segmental performance: The crop protection segment grew by 54% (YoY) to INR 2348mn on the back of strong volume growth in existing products and commercialization of a new product from their newly built facility in Panoli Pharmaceutical segment revenue surged by 32% to INR 2,977mn based on increased volumes of existing API Generics and CDMO products. During the quarter, the company has filled US DMF for Favipiravir API to supporting both domestic and global markets. Despite 129bps contraction in gross margin, EBITDA margin managed to improve by 188bps to 20.5%, was 142bps...
Number of FII/FPI investors decreased from 58 to 50 in Jun 2021 qtr
Hikal Ltd.    
06 Nov 2020
520.80
-1.45%
BP Wealth
INR3,368mn mainly driven by strong growth in the Pharmaceutical segment. On segmental performance: The crop protection segment de grew by 17.9% (YoY) to INR 926mn and 12.7% (YoY) due to deferment of orders worth INR400mn which is expected to be supplied largely in Q3FY21. Pharmaceutical segment revenue surged by 34.1% to INR 2,793mn led by strong volume off-take supported by new capacity at Bangalore unit which was commissioned late last year. Despite 554bps contraction in gross margin, EBITDA margin managed to improve by 58bps to18.8%, was 29bps above our estimate. EBITDA margin was supported by 11% (YoY) decline in employee cost and flat other expenses in the growing topline. EBIT margin of the Crop protection segment declined by 1044bps...
Number of MF schemes decreased from 11 to 2 in Jun 2021 qtr
Hikal Ltd.    
05 Nov 2020
520.80
-1.45%
buy
ICICI Securities Limited
Q2FY21 revenues grew a decent 15.8% YoY to | 372 crore on the back of 34.1% YoY growth in pharma segment to | 279 crore. Crop protection segment fell 17.9% YoY to | 93 crore due to deferral of | 40 crore worth of shipment to Q3FY21. EBITDA for the quarter came in at | 70 crore, up 19.6% YoY (including Covid related expenses of | 1.1 crore). EBITDA margins expanded 58 bps YoY to 18.8% due to lower staff & other expenses, partly offset by lower gross margins. Adjusted PAT grew 23.8% YoY to | 27 crore in line with operational performance. Delta vis-a-vis EBITDA was due to...
default
Hikal Ltd. has gained 278.76% in the last 1 Year
Hikal Ltd.    
22 Jun 2020
520.80
-1.45%
BP Wealth
revenues. EBIT margin of Crop protection segment improved by 302bps (YoY) with ~46% contribution Target Price (INR) to overall EBIT. Pharmaceutical segment EBIT margin contracted by 45bps with ~54% contribution to overall EBIT. PAT came below our estimate at INR245mn (est INR329mn) dragged by operationally weak performance and higher tax expenses (35.1% vs 30.8%). On RM Sourcing from China: Hikal...
default
Hikal Ltd. is trading above all available SMAs
Hikal Ltd.    
20 Jun 2020
520.80
-1.45%
ICICI Securities Limited
Hikal ventured into the pharma API business by virtue of acquisition of Novartis' Panoli plant in the year 2000. In a short span of time, banking on its chemistry skills, the company has been able to tap incremental customers via the CDMO route. Hikal also operates as a dedicated API supplier as it expands its portfolio. We expect the pharma segment to grow at 13.1% CAGR in FY20-22E to | 1135.3 crore on the back of new offerings and repeat business from CDMO customers. Crop protection growth to piggyback on client relationship...
Hikal Ltd. has an average target of 345.00 from 2 brokers.
Hikal Ltd.    
07 Feb 2020
520.80
-1.45%
ICICI Securities Limited
Hikal ventured into the pharma API business by virtue of acquisition of Novartis' Panoli plant in 2000. In a short span of time, banking on its chemistry skills, the company has been able to tap incremental customers via the CDMO route. Hikal also operates as a dedicated API supplier as it expands its portfolio. We expect the pharma segment to grow at a CAGR of...
Hikal Ltd. has gained 278.76% in the last 1 Year
Hikal Ltd.    
29 Oct 2019
520.80
-1.45%
ICICI Securities Limited
Hikal ventured into the pharma API business by virtue of acquisition of Novartis' Panoli plant in 2000. In a short span of time, banking on its chemistry skills, the company has been able to tap incremental customers via the CDMO route. Hikal also operates as a dedicated API supplier as it expands its portfolio. We expect the pharma segment to grow at a CAGR of...
Hikal Ltd. has gained 138.73% in the last 3 Months
Hikal Ltd.    
29 Oct 2019
520.80
-1.45%
BP Wealth
custom duty) of INR154mn. The company posted revenues of INR 3,211mn with 18.7% YoY decline which was below our estimate of INR,4,845mn. Multiple factors affected revenue growth during the quarter such as 1) Crop protection business was affected by heavy flooding at Mahad facility in the month of august which led to temporary production shut down.2) Pharmaceutical business faced issue at taloja facility where MIDC had cut 50% of the water supply to all industries in that region during Q2 and destocking of some of the products by innovator clients led to postponement in product...
Hikal Ltd. has gained 138.73% in the last 3 Months